COVID-19 patients are to receive second life-saving treatment for hospitalised patients outside of intensive care
Thousands more lives could be saved as UK clinical trials show tocilizumab reduced the risk of death by 14% for patients on oxygen on top of benefits from dexamethasone
Treatment will help reduce pressures on hospitals and improve outcomes for patients
Thousands more NHS patients who are hospitalised due to COVID-19 will be able to receive life-saving treatment tocilizumab, the government has announced.
The drug reduced the relative risk of death by 14% and reduced the time spent in hospital by 5 days when used for patients on oxygen and in addition to the corticosteroid dexamethasone.
IONIA, MICH The Michigan Department of Corrections (MODC) has learned of the detection of the SARS-CoV-2, B.1.1.7 variant at the Bellamy Creek Correctional
.
The study will run for a 13-month period and will recruit over 800 patients across eight sites in the UK, including London â St Georgeâs and UCL, Oxford, Southampton, Birmingham, Bristol, Nottingham and Liverpool.
Com-COV has eight different arms that will test eight different combinations of doses and dose intervals. This is tentative and subject to change should more COVID-19 vaccines be approved for use in the UK. The eight arms include the following dose combinations:
Pfizer/BioNTech and Pfizer/BioNTech - 28 days apart
Pfizer/BioNTech and Pfizer/BioNTech - 12 weeks apart â (control group)
Oxford/AstraZeneca and Oxford/AstraZeneca - 28 days apart
World-first COVID-19 alternating dose vaccine study launches in UK — Agenparl agenparl.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from agenparl.eu Daily Mail and Mail on Sunday newspapers.